Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $87.85.

Several analysts have issued reports on RARE shares. Royal Bank of Canada initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, May 3rd. Robert W. Baird lifted their target price on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Wedbush cut their price target on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Thomas Richard Kassberg sold 11,509 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the transaction, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at approximately $12,623,452.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the transaction, the executive vice president now owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew K. Fust sold 12,195 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $50.88, for a total value of $620,481.60. Following the completion of the transaction, the director now owns 14,860 shares of the company’s stock, valued at $756,076.80. The disclosure for this sale can be found here. Insiders sold a total of 32,116 shares of company stock worth $1,645,983 over the last 90 days. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Ultragenyx Pharmaceutical by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock worth $414,764,000 after acquiring an additional 1,440,264 shares during the last quarter. RTW Investments LP grew its position in Ultragenyx Pharmaceutical by 27.4% in the 4th quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock worth $329,340,000 after purchasing an additional 1,481,997 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Ultragenyx Pharmaceutical by 0.4% in the third quarter. Wellington Management Group LLP now owns 5,195,880 shares of the biopharmaceutical company’s stock valued at $185,233,000 after purchasing an additional 18,359 shares during the period. Sands Capital Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 59.8% during the fourth quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock valued at $196,923,000 after buying an additional 1,540,791 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 11.4% during the fourth quarter. Federated Hermes Inc. now owns 2,446,500 shares of the biopharmaceutical company’s stock worth $116,992,000 after buying an additional 250,000 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Down 1.0 %

Shares of RARE stock opened at $41.56 on Friday. The company has a market cap of $3.46 billion, a PE ratio of -5.18 and a beta of 0.68. The company’s fifty day simple moving average is $46.65 and its 200-day simple moving average is $44.33. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The company had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. During the same period last year, the business earned ($2.33) earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities research analysts expect that Ultragenyx Pharmaceutical will post -6.38 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.